3-Ethyl-6-methoxy-benzofuran | 29040-42-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 3-Ethyl-6-methoxy-benzofuran
• 英文别名: 3-Ethyl-6-methoxy-1-benzofuran；3-ethyl-6-methoxy-1-benzofuran
• CAS: 29040-42-4
• 化学式: C₁₁H₁₂O₂
• 分子量: 176.215
• InChiKey: QPTHKPDLKHGBHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  22.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-Ethyl-6-methoxy-benzofuran 在 palladium on activated charcoal 氢气 、 三溴化硼 、 caesium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 邻二氯苯 为溶剂， -10.0~20.0 ℃ 、101.33 kPa 条件下， 反应 1.5h， 生成 3-ethyl-6-hydroxy-7-propylbenzofuran
  参考文献：
  名称：

  Phenylacetic acid derivatives as hPPAR agonists

  摘要：

  Beginning with the weakly active lead structure 1, a new series of WAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. Further manipulation afforded benzofurans 6 and 7. Compound 7 was of comparable potency as a glucose and triglyceride lowering agent in insulin resistant rodents to BRL 49653. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00115-x
• 作为产物：
  描述：

  1-(3-Methoxy-phenoxy)-butan-2-one 在 甲烷磺酸 作用下， 以 二氯甲烷 为溶剂， 生成 3-Ethyl-6-methoxy-benzofuran
  参考文献：
  名称：

  Phenylacetic acid derivatives as hPPAR agonists

  摘要：

  Beginning with the weakly active lead structure 1, a new series of WAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. Further manipulation afforded benzofurans 6 and 7. Compound 7 was of comparable potency as a glucose and triglyceride lowering agent in insulin resistant rodents to BRL 49653. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00115-x

文献信息

• 一种1,2,3,4-四氢苯并[4,5]呋喃[2,3-C]吡啶衍生物的制备方法
  申请人：浙江大学

  公开号：CN114276359B

  公开（公告）日：2023-05-05

  本发明公开了一种1,2,3,4‑四氢苯并[4,5]呋喃[2,3‑C]吡啶衍生物的制备方法，其包括如下步骤：3‑烷基苯并呋喃，甲醛和伯胺类化合物或其盐在溶剂中发生三组分Mannich反应。反应完成后，经后处理得到所述的1,2,3,4‑四氢苯并[4,5]呋喃[2,3‑C]吡啶衍生物；该制备方法以苯并呋喃参与连续的两次Mannich反应，在温和的条件下实现了苯并呋喃和哌啶环的快速并联，反应高效简洁快速，收率较高，对于有机合成和药物化学具有深远意义。
• <i>o</i>-Quinone Methides via Oxone-Mediated Benzofuran Oxidative Dearomatization and Their Intramolecular Cycloaddition with Carbonyl Groups: An Expeditious Construction of the Central Tetracyclic Core of Integrastatins, Epicoccolide A, and Epicocconigrone A
  作者：Atul A. More、Chepuri V. Ramana

  DOI：10.1021/acs.orglett.5b03707

  日期：2016.2.5

  The intramolecular cycloaddition of o-quinone methides (o-QMs) with a carbonyl group has been envisaged and executed successfully in the context of constructing the complex and rare [6,6,6,6]-tetracyclic core found in the integrastatins, epicoccolide A, and epicocconigrone A. These transient o-QMs were generated easily from the oxidative dearomatization of the corresponding C2-(aryl)benzofuran by employing Oxone in acetone-water at rt. The subsequent cydoaddition with the carbonyl (or conjugated olefin) present on the C2-aryl group was spontaneous.
• IL-17A MODULATORS AND USES THEREOF
  申请人：DiCE Alpha, Inc.

  公开号：US20210101886A1

  公开（公告）日：2021-04-08

  The disclosure herein provides compounds and pharmaceutical compositions for the modulation of IL-17A useful for the treatment of inflammatory conditions, such as psoriasis.
• Phenylacetic acid derivatives as hPPAR agonists
  作者：Conrad Santini、Gregory D Berger、Wei Han、Ralph Mosley、Karen MacNaul、Joel Berger、Thomas Doebber、Margaret Wu、David E Moller、Richard L Tolman、Soumya P Sahoo

  DOI：10.1016/s0960-894x(03)00115-x

  日期：2003.4

  Beginning with the weakly active lead structure 1, a new series of WAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. Further manipulation afforded benzofurans 6 and 7. Compound 7 was of comparable potency as a glucose and triglyceride lowering agent in insulin resistant rodents to BRL 49653. (C) 2003 Elsevier Science Ltd. All rights reserved.